GlassScriptPhysician profile
Sasha Sharifi
NPI 1639675176
$3,085.23
in general payments reported to CMS, 2019-2025
16 companies · $99.89 in 2025
The $99.89 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.92 · 2022: $531 · 2023: $1,098 · 2024: $1,307 · 2025: $99.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155 · Travel and Lodging: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.75 |
| Travel and Lodging | $350.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $701.26 | 2023-2024 | Turbohawk, Onyx Frontier |
| Boston Scientific Corporation | $674.29 | 2023-2025 | Rotablator Rotational Atherectomy System Console Kit, General - Stents, Lux-Dx Insertable Cardiac Monitor |
| Abiomed | $259.67 | 2023-2024 | Impella |
| Grifols USA, LLC | $235.14 | 2023-2024 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $227.05 | 2022-2023 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.81 | 2022-2024 | Jardiance |
| Pfizer INC. | $166.22 | 2021-2022 | |
| United Therapeutics Corporation | $164.23 | 2024 | Tyvaso |
| Amgen INC. | $160.03 | 2024 | Repatha |
| Merck Sharp & Dohme LLC | $149.48 | 2022-2023 | Verquvo, Belsomra |
| Novo Nordisk INC | $76.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.01 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $21.49 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.99 | 2024 | Xarelto |
| Philips North America LLC | $15.57 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $15.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Sharifi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.